Latest Breaking News On - Jeremym shefner - Page 1 : comparemela.com

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesJeremym shefnerBarrow neurological instituteDrug administrationNeurosense therapeutics ltdEuropean medicines agencyPrnewswire neurosense therapeutics ltdEuropean network for the cureSense therapeuticsConfidence intervalEuropean networkRisk factorSeeing primecRating scale revisedInvestigator initiated trial

Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024

Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesMichaelr haydenJina swarzJeremym shefnerClinical trials in movement disordersSv health investorsProgram numberDrug administrationAmerican academy of neurology annual meetingBarrow neurological instituteDepartment of neurologyMovement disordersInvestment fundAmerican academy of neurologyAmerican academy

Prilenia Therapeutics B V : Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024

Prilenia Therapeutics B V : Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDennis riedlJeremym shefnerMichaelr haydenJina swarzClinical trials in movement disordersBarrow neurological instituteSv health investorsInvestment fundProgram numberMovement disordersAmerican academy of neurologyDepartment of neurologyAmerican academy of neurology annual meetingCommunications teamDrug administration

Neurosense Therapeutics (NRSN) Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Neurosense Therapeutics (NRSN) Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Erez eitanAvital pushettVivian droryJeremym shefnerShiran zimriNeurosense head of scientific programBarrow neurological instituteClinical researchNeurosense therapeutics ltdSense therapeuticsAmyotrophic lateral sclerosisFrontotemporal degenerationScientific programNeuromuscular diseases unitTel aviv sourasky medical centerPrincipal investigator

NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesErez eitanVivian droryJeremym shefnerShiran zimriNeurosense head of scientific programBarrow neurological instituteDrug administrationNeurosense therapeutics ltdClinical researchEuropean medicines agencyNeuromuscular diseases unitTel aviv sourasky medical centerPrincipal investigatorChief medical officerChief scientific officer